CELCUITY INC
CELCNASDAQ🏆 #1531 by market capEarnings Nov 18 · PostUS Equity
$69.52—
Last available close · quote unavailableTrack CELC
Get earnings, price moves & breaking news on Telegram
24h—
7d▲ 5.9%
14d▲ 15.3%
30d▼ 10.1%
ytd▼ 30.2%
1y▼ 6.0%
🏦Market Cap
$3.40B
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- —
- 52-Week Range
- $53.54 – $151.02
- Volume (shares)
- —
- Avg Volume (shares)
- —
- Shares Outstanding
- 48.9M
- Next Earnings
- 2026-11-18
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-4.30
- Dividend Yield
- —
CELCUITY INC
CELCFinancial Trends
Financial history unavailable.
StockOtter · stockotter.spaceAbout CELCUITY INC
Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
⚡Momentum★★★★★
Overall Score
Insufficient data
—/100
Analyst Ratings
ⓘConsensus
Buy
18 analysts
Strong Buy7
Buy10
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026
Latest News & Updates
News unavailable.